Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) expects net profit attributable to shareholders in the range of 35 million yuan and 52 million yuan in 2024, 52% to 68% lower than 108.6 million yuan logged in 2023, a Friday Hong Kong bourse filing said.
The pharmaceutical company attributed the expected reduction in profit to an increase in research and development expenses, additional expenses due to scaling up production processes for two of its projects, and getting a new subsidiary operational.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments